A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest from Elizabeth Cairns
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
The company is trading below cash after admitting that an adverse event in a Rett syndrome trial left a patient critically ill.
Dosing eftilagimod alpha on top of Merck & Co’s blockbuster appears to improve survival, though more robust data are needed.
Drug development costs shrank thanks in part to trial failures.
The German group is doubling down on the hot PD-(L)1 x VEGF-A bispecific space but will still have to contend with Summit and Akeso’s more advanced rival.
Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.